Niraxx Light Therapeutics Announces New Study Validating Personalized Light Therapy
BLOG “The joint study has confirmed that personalized PBM dosing is key to MDD treatment.” Post Date December 20, 2021 Share
Niraxx Light Therapeutics Announces Initiation of a Phase 2 Depression Clinical Trial
[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] “We think the device’s wearability—ability to deliver treatment whenever and wherever—will change the care paradigm for depression.” [/et_pb_text][et_pb_text _builder_version=”4.4.5″ text_font=”Vollkorn||||||||” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”] Irvine, Calif. — Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced the initiation of a […]
